Post-transplant cyclophosphamide (PT-Cy) is the backbone of GvHD prophylaxis following haploidentical hematopoietic cell transplantation (haplo-HCT). PT-Cy has also been used in matched related (MRD) and unrelated (MUD) settings. It is not known whether outcomes are similar between haplo-HCT and MRD/MUD HCT when PT-Cy is used. We performed a retrospective analysis of 83 patients with AML who underwent HCT (using PT-Cy-based GvHD prophylaxis) from MRD, MUD or haploidentical donors. The groups were similar in baseline characteristics with the exception of older age in the MRD/MUD group (P = 0.012). In multivariate analysis, the effect of donor type (MRD/MUD vs haploidentical) on transplant outcomes was not significant in any of the models except for faster neutrophil recovery after MRD/MUD transplants (hazard ratio: 2.21; 95% confidence interval: 1.31-3.72, P = 0.002). In conclusion, we showed similar outcomes in MRD/MUD vs haploidentical HCT (except slower count recovery following haplo-HCT) when PT-Cy is used for GvHD prophylaxis. Although slower count recovery following haplo-HCT (compared with MRD/MUD transplants without PT-Cy) has been attributed to using PT-Cy, our results suggest that HLA disparity is the primary cause of this difference. Furthermore, our analysis supports PT-Cy as a viable option for GvHD prophylaxis after MRD/MUD transplants.
INTRODUCTION
HLA-haploidentical hematopoietic cell transplantation (haplo-HCT) using post-transplant high-dose cyclophosphamide (PT-Cy) is an increasingly popular alternative strategy for allogeneic HCT in patients who lack an HLA-matched related (MRD) or unrelated donor (MUD).
1,2 PT-Cy has been used in the MRD/MUD setting as well, with encouraging results. 3, 4 The objective of the present study was to answer the intriguing and unexplored question of whether outcomes are similar between haplo-HCT and MRD/MUD HCT when PT-Cy is used for GvHD prophylaxis. A second goal of this study was to investigate whether the reported slower count recovery following haplo-HCT (compared with MRD/MUD transplants) 5, 6 is because of the use of PT-Cy per se or HLA disparity between the donor and recipient. We included patients only if they had AML and received PT-Cy-based GvHD prophylaxis. The former inclusion criterion (disease uniformity) minimized the inevitable heterogeneity that often confounds comparative analyses of different transplant approaches. The latter criterion (all patients receiving PT-Cy) allowed us to investigate our second goal without the potential confounding effect of PT-Cy.
PATIENTS AND METHODS
Medical records of all patients with AML who underwent their first T-replete allogeneic HCT at our institution (2010-2015) were retrospectively reviewed. The inclusion criteria were: (1) using G-CSFmobilized peripheral blood as graft source, (2) using a matched related/ unrelated or haploidentical donor and (3) using PT-Cy (50 mg/kg on days +3 and +4), a calcineurin inhibitor and mycophenolate mofetil as GvHD prophylaxis. Filgrastim 5 μg/kg daily was administered starting day +5 until neutrophil recovery. Molecular typing was at an allele or allele group level for HLA-A, -B, -C and -DRB1.
Cytogenetic risk classification was according to standard criteria. 7 Active disease was defined as lack of complete remission on the last bone marrow biopsy performed within 4 weeks before conditioning initiation. Conditioning intensity was defined as myeloablative or reduced intensity using the consensus criteria. 8 The day of platelet recovery was defined as the first day on which the platelet count reached or exceeded 20 × 10 9 /L without transfusion. The day of neutrophil recovery was defined as the first of 3 consecutive days on which the absolute neutrophil count exceeded 0.5 × 10 9 /L. Donor engraftment was determined by a PCR-based assay for STRs from bone marrow samples or peripheral blood mononuclear cells, 9 and defined as donor chimerism 495%, and graft failure as o 5% not due to relapse. The International Bone Marrow Transplant Registry criteria were used for acute GvHD staging and grading, 10 and the National Institute of Health criteria were used to determine chronic GvHD severity.
11
Graft failure, relapse or death (all without GvHD) were considered competing risks for GvHD; relapse was considered a competing risk for nonrelapse mortality; death without relapse was considered competing risk for relapse; and death without count recovery was considered a competing risk for count recovery. Medians were compared using the Mann-Whitney U-test, and proportions using the χ 2 test (and Fisher's exact test when appropriate). Kaplan-Meier curves with the log-rank test and Cox regression were used for time-to-event analysis. Competing risk cumulative incidence analysis was performed using the Fine and Gray method.
12 R 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria) was used for statistical analysis.
RESULTS
A total of 83 patients (62 haploidentical and 21 MRD/MUD) were included ( Table 1) . The most common conditioning regimens in the haploidentical group were fludarabine (Flu), cyclophosphamide (Cy) and TBI (Flu 30 mg/m 2 /day days − 6 to − 2, Cy 14.5 mg/ kg/day days − 6 and − 5 and TBI 2 Gy day − 1; 45%) and Flu/ fractionated TBI (Flu 30 mg/m 2 /day days − 7 to − 5 and TBI 150 cGy twice daily days − 4 to − 1; 37%). The most common conditioning regimens in MRD/MUD groups were Flu/Cy/TBI (29%), Flu/Bu (Flu 30 mg/m 2 /day days − 6 to − 2 and Bu 3.2 mg/ kg days − 5 and − 4; 24%) and Flu/Bu/Cy (Flu 25 mg/m 2 /day days − 6 to − 2, Bu 3.2 mg/kg/day days − 7 to − 4 and Cy 14.5 mg/kg/ day days − 3 and − 2; 24%). Donor-specific antibodies were present in 7 of the 43 haplo-HCT recipients who were tested for these antibodies. The groups were similar in all baseline characteristics with the exception of older age in the MRD/MUD vs haploidentical group (median 64 (range 18-74) vs 54 (range 19-73) years, respectively; P = 0.012). In addition, a marginally significant difference was found between the groups in the frequency of major ABO mismatch (38% vs 18% in MRD/MUD vs haploidentical transplants, respectively; P = 0.06) and active disease (19% vs 40%, respectively; P = 0.08).
Primary graft failure occurred in one patient (haploidentical group). The results of time-to-event analysis are shown in Figure 1 . The median follow-up for survivors was 18 months. There were no significant differences between haploidentical and MUD/MRD groups in 1-year overall survival (53% vs 58%, respectively; P = 0.31), 1-year nonrelapse mortality (22% vs 16%, respectively; P = 0.30), 1-year relapse (31% vs 26%, respectively; P = 0.70), 6-month acute GVHD II-IV (40% vs 19%, respectively; P = 0.07) and 1-year moderate/severe chronic GVHD (6% vs 5%, respectively; P = 0.86). Although platelet recovery appeared slower in the haploidentical group (median time to recovery 23 vs 15 days and 30-day recovery rate 71% vs 81%, respectively), the difference did not reach statistical significance (P = 0.12) and the apparent large gap between the curves was associated with large variations and hence wide confidence bands for the curves. However, neutrophil recovery was significantly slower in the haploidentical group (median time to recovery 16 vs 14 days and 30-day recovery rate 87% vs 100%, respectively; P = 0.011).
According to the results of univariate analysis, donor type (MRD/MUD vs haploidentical), age, major ABO mismatch and disease status were used in multivariate analysis ( Table 2 ). All variables met the proportional hazards assumption. The effect of donor type on transplant outcomes was not significant in any of the multivariate models with the exception of faster neutrophil recovery after MRD/MUD transplants (hazard ratio: 2.21; 95% confidence interval: 1.31-3.72, P = 0.002). Platelet recovery was marginally significantly faster after MRD/MUD transplants (hazard ratio: 1.73; 95% confidence interval: 0.96-3.11, P = 0.07).
DISCUSSION
A number of studies have now demonstrated no significant difference in outcomes between haplo-HCT and MRD/MUD transplants. [13] [14] [15] [16] [17] In these studies, however, GvHD prophylaxis in the MRD or MUD group was not PT-Cy based. Furthermore, none of the previous studies of PT-Cy in the MRD/MUD setting compared their results with PT-Cy-based haplo-HCT. The retrospective nature of the available studies (including this study) precludes definitive conclusions. Nonetheless, including cohorts that are similar in a number of important baseline characteristics can minimize the effect of confounding variables. In the present study, we attempted to make the groups as homogenous as Abbreviations: HCT-CI = hematopoietic cell transplantation-specific comorbidity index; MRD = matched related (9 patients); MUD = matched unrelated (12 patients). *P o0.05.
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possible by focusing on patients with the same underlying disease (AML) and the same GvHD prophylaxis (PT-Cy based). In addition, baseline differences between the groups were controlled for in multivariate analysis.
Our results from a cohort of AML patients undergoing allogeneic HCT do not show a difference in transplant outcomes between MRD/MUD vs haploidentical HCT when PT-Cy is used for GvHD prophylaxis. The only exception is slower count recovery following haplo-HCT. Although slower count recovery following haplo-HCT (compared with MRD/MUD transplants without PT-Cy) has traditionally been attributed to the use of PT-Cy, disease and GvHD prophylaxis uniformity of patients in our study suggests that HLA disparity, rather than PT-Cy, is the primary cause of slower count recovery in haplo-HCT. The effect of HLA disparity may be at least partly via donor-specific antibodies. 18 Finally, our results support the use of PT-Cy-based regimens as a viable option for GvHD prophylaxis after MRD/MUD transplants.
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